| Market Cap | 53.50M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -24.19M | Forward P/E | -1.55 | EPS next Y | - | 50D Avg Chg | 4.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -13.00% |
| Dividend | N/A | Price/Book | 0.72 | EPS next 5Y | - | 52W High Chg | -73.00% |
| Recommedations | 2.00 | Quick Ratio | 13.72 | Shares Outstanding | 172.21M | 52W Low Chg | 42.00% |
| Insider Own | 30.76% | ROA | -15.71% | Shares Float | 121.93M | Beta | 0.92 |
| Inst Own | 7.51% | ROE | -28.36% | Shares Shorted/Prior | 759.72K/1.17M | Price | 0.31 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 1,418,200 | Target Price | - |
| Oper. Margin | - | Earnings Date | Nov 7 | Volume | 2,678,186 | Change | 8.07% |
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. As of September 16, 2022, Tyme Technologies, Inc. operates as a subsidiary of Syros Pharmaceuticals, Inc.
| Canaccord Genuity | Buy | Jan 4, 18 |
| H.C. Wainwright | Buy | Dec 15, 17 |
| Evercore ISI Group | Outperform | Nov 17, 17 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Demurjian Michael | 10% Owner 10% Owner | Sep 06 | Sell | 0.25 | 160,000 | 40,000 | 22,448,846 | 09/07/22 |
| Demurjian Michael | 10% Owner 10% Owner | Aug 22 | Sell | 0.29 | 160,000 | 46,400 | 22,608,846 | 08/23/22 |
| Demurjian Michael | 10% Owner 10% Owner | Jul 25 | Sell | 0.29 | 140,000 | 40,600 | 22,768,846 | 07/26/22 |
| Demurjian Michael | 10% Owner 10% Owner | Jul 11 | Sell | 0.29 | 140,000 | 40,600 | 22,908,846 | 07/12/22 |
| Demurjian Michael | 10% Owner 10% Owner | Jun 28 | Sell | 0.2679 | 60,000 | 16,074 | 23,048,846 | 06/28/22 |
| Demurjian Michael | 10% Owner 10% Owner | Jun 27 | Sell | 0.2622 | 60,000 | 15,732 | 23,108,846 | 06/27/22 |
| Hoffman Steve | Director Director | Jun 08 | Sell | 0.27 | 156,250 | 42,188 | 20,178,816 | 06/10/22 |
| Demurjian Michael | 10% Owner 10% Owner | May 31 | Sell | 0.25 | 120,000 | 30,000 | 23,288,846 | 06/02/22 |
| Demurjian Michael | 10% Owner 10% Owner | May 17 | Sell | 0.2508 | 50,000 | 12,540 | 23,408,846 | 05/17/22 |
| Demurjian Michael | 10% Owner 10% Owner | May 16 | Sell | 0.2501 | 50,000 | 12,505 | 23,458,846 | 05/17/22 |
| Hoffman Steve | Director Director | May 09 | Sell | 0.3 | 156,250 | 46,875 | 20,491,316 | 05/11/22 |
| Demurjian Michael | 10% Owner 10% Owner | May 02 | Sell | 0.32 | 100,000 | 32,000 | 23,508,846 | 05/03/22 |
| Demurjian Michael | 10% Owner 10% Owner | Apr 12 | Sell | 0.335 | 20,000 | 6,700 | 23,688,846 | 04/13/22 |
| Hoffman Steve | Director Director | Apr 11 | Sell | 0.32 | 156,250 | 50,000 | 20,803,816 | 04/13/22 |
| Demurjian Michael | 10% Owner 10% Owner | Apr 04 | Sell | 0.3502 | 20,000 | 7,004 | 23,708,846 | 04/04/22 |
| Hoffman Steve | Director Director | Mar 28 | Sell | 0.35 | 156,250 | 54,688 | 20,960,066 | 04/01/22 |
| Demurjian Michael | 10% Owner 10% Owner | Mar 28 | Sell | 0.345 | 20,000 | 6,900 | 23,728,846 | 03/29/22 |
| Demurjian Michael | 10% Owner 10% Owner | Mar 21 | Sell | 0.329 | 20,000 | 6,580 | 23,748,846 | 03/21/22 |
| Demurjian Michael | 10% Owner 10% Owner | Mar 14 | Sell | 0.2962 | 20,000 | 5,924 | 23,768,846 | 03/14/22 |
| Biehl James | Chief Legal Officer Chief Legal Officer | Feb 15 | Buy | 0.34 | 20,000 | 6,800 | 105,000 | 02/16/22 |
| Demurjian Michael | 10% Owner 10% Owner | Jan 31 | Sell | 0.3357 | 20,000 | 6,714 | 23,888,846 | 01/31/22 |
| Hoffman Steve | Chief Science Office.. Chief Science Officer | Jan 25 | Sell | 0.43 | 156,250 | 67,188 | 21,585,066 | 01/27/22 |
| Demurjian Michael | 10% Owner 10% Owner | Jan 24 | Sell | 0.52 | 20,000 | 10,400 | 23,908,846 | 01/25/22 |
| Demurjian Michael | 10% Owner 10% Owner | Jan 20 | Sell | 0.59 | 320 | 189 | 23,928,846 | 01/21/22 |
| Hoffman Steve | Chief Science Office.. Chief Science Officer | Nov 29 | Sell | 0.73 | 156,250 | 114,062 | 22,210,066 | 12/01/21 |
| Hoffman Steve | Chief Science Office.. Chief Science Officer | Oct 26 | Sell | 0.97 | 156,250 | 151,562 | 22,522,566 | 10/28/21 |
| Hoffman Steve | Chief Science Office.. Chief Science Officer | May 13 | Sell | 1.2 | 82,500 | 99,000 | 24,240,248 | 05/13/21 |
| Hoffman Steve | Chief Science Office.. Chief Science Officer | Apr 29 | Sell | 1.57 | 83,500 | 131,095 | 24,322,748 | 04/29/21 |
| Van Tornout Jan M | Acting Chief Medical.. Acting Chief Medical Officer | Apr 14 | Buy | 1.75 | 1,809 | 3,166 | 1,809 | 04/14/21 |
| Hoffman Steve | Chief Executive Offi.. Chief Executive Officer | Nov 05 | Sell | 0.91 | 40,881 | 37,202 | 25,871,525 | 11/05/20 |
| Hoffman Steve | Chief Executive Offi.. Chief Executive Officer | Oct 23 | Sell | 0.98 | 37,842 | 37,085 | 25,912,406 | 10/23/20 |
| Hoffman Steve | Chief Executive Offi.. Chief Executive Officer | Sep 24 | Sell | 0.95 | 62,500 | 59,375 | 26,012,748 | 09/24/20 |